DexCom, Inc. vs FedEx Corporation — how do they compare? DexCom, Inc. trades at $83.92 (market cap $31.86B), while FedEx Corporation trades at $290.52 (market cap $69.04B). The key difference: FedEx Corporation is far larger — about 2.2× DexCom, Inc.'s market cap, and FedEx Corporation pays a 1.67% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and FedEx Corporation for 87 Days on average.
| DXCM | FDX | |
|---|---|---|
Market Cap | $31.86B | $69.04B |
Volume | 3,607,070 | 1,287,367 |
Sector | Health | Industrials |
52-Week High | $92.34 | $339.35 |
52-Week Low | $54.84 | $180.87 |
Typical Hold Time | 62 Days | 87 Days |
Enterprise Value | $31.32B | $98.68B |
Dividend Yield | — | 1.67% |
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
FedEx (FDX) trades at $289.04, showing minimal daily change. The stock exhibits a bearish technical signal with key support at $288 and resistance at $290. Fundamentally, the company maintains stable profitability with a net income margin of 4.68% and a P/E ratio of 15.73, while recent earnings beats in Q4 2025 and Q1 2026 highlight operational strength. Positive developments include a $300 million electric truck order and shareholder approval of executive compensation, though rising fuel prices present a near-term headwind.
The outlook for FDX is cautiously optimistic, supported by analyst consensus favoring a buy rating with a $307.55 price target. Investment appeal lies in its reasonable valuation and dividend yield, but risks include margin pressure from fuel costs, competitive intensity, and macroeconomic sensitivity. The stock's trajectory will likely hinge on execution of cost initiatives and freight demand trends.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →